Prescription requirement under Section 503A of the Federal Food, Drug, and Cosmetic Act
Specifically, 5-amino-1MQ and 7-amino-1MQ exhibited high passive and active transport across membrane, with no detectable efflux observed in the Caco-2 cell assay
Maryland Trim Clinic (MTC) in Laurel, MD Navigating the ceiling dose of a powerful GLP-1 medication requires expert, hands-on medical oversight
Does taking collagen reduce wrinkles or improve skin hydration and elasticity
PMCID: PMC6302565 Acke FR, Swinnen FK, Malfait F, Dhooge IJ, De Leenheer EM
The Substances on the Table These are the drugs being reviewed and the medical uses FDA will be evaluating: July 23, 2026: BPC-157 (free base and acetate) ulcerative colitis KPV (free base and acetate) wound healing and inflammatory conditions TB-500 (free base and acetate) wound healing MOTs-C (free base and acetate) obesity and osteoporosis July 24, 2026: Emideltide / DSIP (delta sleep-inducing peptide, free base and acetate) opioid withdrawal, chronic insomnia, and narcolepsy Semax (free base and acetate) cerebral ischemia, migraine, and trigeminal neuralgia Epitalon (free base and acetate) insomnia If any or all of these substances are added to the 503A Bulks List following this process, it would formalize the legal pathway for licensed pharmacists and physicians to compound them for patients